ZA985376B - Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals - Google Patents

Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Info

Publication number
ZA985376B
ZA985376B ZA985376A ZA985376A ZA985376B ZA 985376 B ZA985376 B ZA 985376B ZA 985376 A ZA985376 A ZA 985376A ZA 985376 A ZA985376 A ZA 985376A ZA 985376 B ZA985376 B ZA 985376B
Authority
ZA
South Africa
Prior art keywords
dismutation
superoxide radicals
synthetic catalysts
analgesic methods
analgesic
Prior art date
Application number
ZA985376A
Other languages
English (en)
Inventor
Daniela Salvemini
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of ZA985376B publication Critical patent/ZA985376B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Catalysts (AREA)
ZA985376A 1997-06-20 1998-06-19 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals ZA985376B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5040297P 1997-06-20 1997-06-20

Publications (1)

Publication Number Publication Date
ZA985376B true ZA985376B (en) 1999-06-21

Family

ID=21965044

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985376A ZA985376B (en) 1997-06-20 1998-06-19 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals

Country Status (12)

Country Link
US (2) US6180620B1 (xx)
EP (1) EP1001752B1 (xx)
JP (1) JP2002506445A (xx)
AT (1) ATE256467T1 (xx)
AU (1) AU733415B2 (xx)
CA (1) CA2294155A1 (xx)
DE (1) DE69820633T2 (xx)
DK (1) DK1001752T3 (xx)
ES (1) ES2215305T3 (xx)
PT (1) PT1001752E (xx)
WO (1) WO1998058636A1 (xx)
ZA (1) ZA985376B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US20060270639A1 (en) * 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US6214817B1 (en) * 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20050171198A1 (en) * 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
CA2309154C (en) 1997-11-03 2010-02-16 Duke University Substituted porphyrins
DK1155019T3 (da) 1999-01-25 2006-04-18 Nat Jewish Med & Res Center Substituerede porphyriner og deres terapeutiske anvendelse
DE60018925T2 (de) 1999-05-27 2006-04-13 Pharmacia Corp.(N.D.Ges.D.Staates Delaware) Biomaterialien, modifiziert mit superoxid-dismutase imitatoren
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US20020072512A1 (en) * 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
EP1347773B1 (en) * 2001-01-05 2010-04-14 Metaphore Pharmaceuticals Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
EP1392328B1 (en) 2001-01-19 2009-08-12 National Jewish Medical and Research Center Medicament for protection in radiotherapy
AU2002236861A1 (en) * 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20040137638A1 (en) * 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
EP1405066B1 (en) * 2001-03-02 2015-06-17 Galera Therapeutics LLC Chromatography of metal complexes
WO2002098431A1 (en) * 2001-06-01 2002-12-12 National Jewish Medical And Research Center Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
EP1417219A4 (en) * 2001-06-08 2005-05-25 Metaphore Pharmaceuticals Inc LIBRARIES OF PEPTIDES, CHIRAL AZACROWNS AND PEPTIDOMIMETICS WITH CONFORMATIONAL CONSTRAINTS AND METHODS OF MAKING THE SAME
US20040266742A1 (en) * 2001-06-26 2004-12-30 Daniela Salvemini Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease
EP1450824A4 (en) * 2001-11-02 2005-09-28 Elan Corp Plc PHARMACEUTICAL COMPOSITION
US7759333B2 (en) * 2001-12-14 2010-07-20 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US6933275B2 (en) * 2002-05-01 2005-08-23 The Board Of Trustees Of The Leland Stanford Junior University Protein kinase C peptides for use in withdrawal
AU2003237500A1 (en) * 2002-06-07 2003-12-22 Duke University Substituted porphyrins
US20030232784A1 (en) * 2002-06-14 2003-12-18 Benedict James J. Hyaluronic acid-associated superoxide dismutase mimics and their use in the treatment of joint pain
US6984636B2 (en) * 2002-08-12 2006-01-10 Medical Research Council Mitochondrially targeted antioxidants
EP1551402A4 (en) * 2002-09-23 2009-05-27 Verion Inc PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
MXPA05005937A (es) * 2002-12-06 2005-08-18 Alcon Inc Imitaciones de superoxido de dismutasa para el tratamiento de trastornos y enfermedades oculares.
CA2505608A1 (en) * 2002-12-06 2004-06-24 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
KR100648618B1 (ko) * 2003-11-19 2006-11-23 주식회사 웰스킨 활성 산소 억제제
AU2004305531B2 (en) * 2003-12-11 2009-11-26 Alcon, Inc. Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
CA2591970C (en) * 2004-12-21 2014-08-19 Metaphore Pharmaceuticals, Inc Polyethylene glycolated superoxide dismutase mimetics
US8217166B2 (en) * 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
US20120301403A1 (en) 2007-06-21 2012-11-29 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
KR100724586B1 (ko) 2005-12-09 2007-06-04 세종대학교산학협력단 수퍼옥사이드 디스뮤타아제 활성을 갖는 고리화합물
ES2725023T3 (es) 2006-10-12 2019-09-18 Galera Labs Llc Métodos para el tratamiento de la mucositis oral
US8486928B2 (en) 2007-11-14 2013-07-16 Galera Therapeutics Super-oxide dismutase mimetics
EP2859916B1 (en) 2008-05-22 2017-11-29 Galera Labs, LLC Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy
ES2600469T3 (es) 2008-05-23 2017-02-09 National Jewish Health Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro
WO2013048965A1 (en) * 2011-09-26 2013-04-04 Galera Therapeutics, Llc Methods for treatment of diseases
RS60558B1 (sr) 2015-08-11 2020-08-31 Galera Labs Llc Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost
EP3582753A4 (en) * 2017-02-15 2020-12-16 Galera Labs, LLC MACROCYCLIC PENTAAZA RING COMPLEXES FOR LOCAL INTESTINAL ADMINISTRATION
IL269915B (en) 2017-04-13 2022-09-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
WO2019152661A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
WO2021163397A1 (en) 2020-02-13 2021-08-19 Teva Pharmaceuticals International Gmbh Solid state forms of avasopasem manganese and process for preparation thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4999347A (en) 1986-08-28 1991-03-12 Sorenson John R J Analgesic method
US5216021A (en) 1986-08-28 1993-06-01 Sorenson John R J Analgesic method
JPS63313581A (ja) * 1987-06-16 1988-12-21 Ube Ind Ltd 修飾ス−パ−オキシドジスムタ−ゼ
EP0598753B1 (en) 1991-07-19 1998-03-18 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CN1088086A (zh) * 1992-12-14 1994-06-22 西北大学 一种新型的护肤保健品
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
KR19990087784A (ko) 1996-03-13 1999-12-27 죤 에이치. 뷰센 초과산화물을 불균등화하기 위한 촉매로서 효과적인 질소함유거대고리 리간드의 망간 또는 철착물의 바이오콘쥬게이트

Also Published As

Publication number Publication date
EP1001752A1 (en) 2000-05-24
EP1001752B1 (en) 2003-12-17
ATE256467T1 (de) 2004-01-15
US6180620B1 (en) 2001-01-30
US6395725B1 (en) 2002-05-28
DK1001752T3 (da) 2004-04-19
DE69820633D1 (de) 2004-01-29
PT1001752E (pt) 2004-05-31
WO1998058636A1 (en) 1998-12-30
AU733415B2 (en) 2001-05-17
ES2215305T3 (es) 2004-10-01
AU8068598A (en) 1999-01-04
JP2002506445A (ja) 2002-02-26
CA2294155A1 (en) 1998-12-30
DE69820633T2 (de) 2004-09-23

Similar Documents

Publication Publication Date Title
ZA985376B (en) Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
FR13C0062I1 (xx)
GB2333453A (en) Colostrinin and uses thereof
MY109880A (en) Substituted biphenylpyridones
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
GB9907461D0 (en) Neurite regeneration
ZA956709B (en) Ionene polymers containing biologically-active anions
ZA966024B (en) Organic nitrogen compounds, their manufacture and use as fuel and lubricant additives.
AU7245898A (en) Methods and devices for delivering opioid analgesics to wounds
BG101139A (en) Heteroatoms-containing cyclopentanopyridyloxazolidinons
NO983945L (no) Isokinoliner som er nyttige som analgetika
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
PT946175E (pt) Utilizacao de uma combinacao de inibidores de h+, k+ -atpase e de glucocorticiodes no tratamento de polipos nasais
HUP0200061A2 (en) Topic tricyclic antidepressants as analgesics
DE60039679D1 (de) Reduktion des molekulargewichts von olefincopolymerisaten
IL131478A0 (en) Methods for treatment of scar tissue
AU2003283055A8 (en) Opioid-receptor antagonists in transdermal systems having buprenorphine
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
IL134479A (en) Transdermal therapeutic system with protection against oral use
EP0590446A3 (de) Benzimidazole und ihre Anwendung als Ladungsstabilisatoren.
DE50002304D1 (en) Tyrosin- und tryptophanhaltige peptide als antioxidantien
ZA981782B (en) The use of levobupivacaine in combination with other drugs
AU6091299A (en) Treatment device, treatment bed to be used therein and the use thereof
GB9900971D0 (en) Safety rail system
SG90720A1 (en) Photoresist compositions with cyclic olefin polymers and additive